SCHEMBL8568448

SCHEMBL8568448

CC(C)(C#N)CCCCCOCC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.46
EGFR P00533 3/20 0.46
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
MAPK1 P28482 1/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
GUSB P08236 1/20 0.45
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
PLA2G4B P0C869 1/20 0.44
PARP10 Q53GL7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SRD5A2 P31213 1/20 0.43
PPARG P37231 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8566469 0.81 TDP1 (0.47) MAOBL3MBTL1
SCHEMBL6760987 0.81 GUSB (0.57) MAOBEGFRRAB9ASMN1; SMN2NPC1
SCHEMBL6893992 0.81 NR4A1 (0.55) MAOBEGFRRAB9ASMN1; SMN2NPC1
SCHEMBL6755906 0.80 LTA4H (0.46) MAOBL3MBTL1
SCHEMBL6899078 0.80 NR4A1 (0.56) MAOBEGFRRAB9ASMN1; SMN2NPC1
SCHEMBL9047885 0.78 NR4A1 (0.57) MAOBEGFRRAB9ASMN1; SMN2NPC1
SCHEMBL8568441 0.77 MAOB (0.54) MAOB
SCHEMBL31032489 0.77 L3MBTL1 (0.46) L3MBTL1
SCHEMBL6756014 0.76 NR4A2 (0.47) MAOBSMN1; SMN2MAPK1NR4A1NR4A2
SCHEMBL1630447 0.75 NR4A1 (0.68) MAOBEGFRRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0735870-A4 USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE LILLY CO ELI (US) 1998-08-19 EP disclosed
EP-0544488-B1 Substituted phenyl phenol leukotriene antagonists LILLY CO ELI (US) 1998-03-11 EP disclosed
WO-1996036347-A1 USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1996-11-21 WO disclosed
EP-0743064-A1 Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease ELI LILLY AND COMPANY (US) 1996-11-20 EP disclosed
EP-0735870-A1 USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1996-10-09 EP disclosed
US-5563164-A TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1996-10-08 US disclosed
US-5478857-A Administering inhibitor of phospholipase A2 ELI LILLY AND COMPANY (US) 1995-12-26 US disclosed
US-5462954-A Antiinflammatory, antiallergens; treating asthma ELI LILLY AND COMPANY (US) 1995-10-31 US disclosed
WO-1995017183-A1 USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1995-06-29 WO disclosed
EP-0544488-A2 Substituted phenyl phenol leukotriene antagonists ELI LILLY AND COMPANY (US) 1993-06-02 EP disclosed